IJMS | Free Full-Text | Targeting NF-κB-Inducing Kinase (NIK) in Immunity, Inflammation, and Cancer
Pharmacological inhibition of NF-κB-inducing kinase (NIK) with small molecules for the treatment of human diseases - RSC Medicinal Chemistry (RSC Publishing)
Recombinant human NFkB Inducing Kinase NIK protein (ab105210) | Abcam
The non-canonical NF-κB pathway in immunity and inflammation | Nature Reviews Immunology
Activation of NF-κB-Inducing Kinase in Islet β Cells Causes β Cell Failure and Diabetes: Molecular Therapy
Catalytic subunits of the phosphatase calcineurin interact with NF-κB-inducing kinase (NIK) and attenuate NIK-dependent gene expression | Scientific Reports
Frontiers | NF-κB Inducing Kinase Regulates Intestinal Immunity and Homeostasis
NHRI researchers report expression of Nik-related kinase in smooth muscle cells attenuates vascular inflammation and intimal hyperplasia – NHRI Communications
Frontiers | The Therapeutic Potential of Targeting NIK in B Cell Malignancies
Cells | Free Full-Text | Inhibitory-κB Kinase (IKK) α and Nuclear Factor-κB (NFκB)-Inducing Kinase (NIK) as Anti-Cancer Drug Targets
NF-κB-inducing kinase activates IKK-α by phosphorylation of Ser-176 | PNAS
Pharmacological inhibition of NF-κB-inducing kinase (NIK) with small molecules for the treatment of human diseases - RSC Medicinal Chemistry (RSC Publishing) DOI:10.1039/D0MD00361A
IJMS | Free Full-Text | Targeting NF-κB-Inducing Kinase (NIK) in Immunity, Inflammation, and Cancer
Pharmacological inhibition of NF-κB-inducing kinase (NIK) with small molecules for the treatment of human diseases - RSC Medicinal Chemistry (RSC Publishing) DOI:10.1039/D0MD00361A
Discovery of a Potent and Selective NF-κB-Inducing Kinase (NIK) Inhibitor That Has Anti-inflammatory Effects in Vitro and in Vivo | Journal of Medicinal Chemistry
Controlling the Fate of NIK: A Central Stage in Noncanonical NF-κB Signaling | Science Signaling
Cells | Free Full-Text | Inhibitory-κB Kinase (IKK) α and Nuclear Factor-κB (NFκB)-Inducing Kinase (NIK) as Anti-Cancer Drug Targets
Functional interplay between NF-κB-inducing kinase and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma | Haematologica